What Survodutide is
Survodutide is an investigational dual agonist built around GLP-1 and glucagon signaling for obesity and liver-metabolic disease research.
Survodutide is grouped under Fat Loss + GLP-1s / Approved / Clinical on PeptideFactCheck because it is one of several next-wave obesity peptides being watched beyond semaglutide and tirzepatide.
The useful starting point is to separate the molecule itself from the internet story around it. It is one of several next-wave obesity peptides being watched beyond semaglutide and tirzepatide.
Why people keep looking it up
It is one of several next-wave obesity peptides being watched beyond semaglutide and tirzepatide.
Survodutide is an investigational dual agonist built around GLP-1 and glucagon signaling for obesity and liver-metabolic disease research.
Survodutide tends to stay in the conversation because it touches a familiar public theme: glp-1 receptor, glucagon receptor, and body weight. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Early human clinical signal without approval-level certainty.
Human data exists, but the drug remains investigational rather than approved.
Mechanistic support follows dual receptor signaling and metabolic-pharmacology rationale.
Why this page carries the current tier: Early human clinical signal without approval-level certainty.
The current seed trail for Survodutide is pulling from 1 literature source, 1 trials source, 1 databases source, and 1 safety source.
Safety, limits, and regulatory context
Category enthusiasm can outrun approval status and long-term outcome certainty.
Survodutide remains investigational in the contexts tracked here.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Survodutide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Survodutide is CID 171378821. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 171378821
- Formula
- C192H289N47O61
- Molecular weight
- 4232
- InChIKey
- MEDXQFAHWBMVIM-PCLHIQTFSA-N
Matched synonyms include Survodutide, 2805997-46-8, BI-456906, GLXC-27923.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Survodutide returns 24 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Survodutide returns 65 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.